Review

mac2 (Cedarlane)

Cedarlane is a verified supplier

Cedarlane manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cedarlane mac2
Mac2, supplied by Cedarlane, used in various techniques. Bioz Stars score: 96/100, based on 398 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mac2/Anti-Mouse%2FHuman+Mac-2+(Galectin-3)%2C+Purified+(Clone+M3%2F38)+(rat+IgG2a)/pm41794821-312-23-25
Average 96 stars, based on 398 article reviews

mac2 - by Bioz Stars, 2026-09

96/100 stars

Images

Fluorescence:

Article Title: Human resistin is critical to activation of the NLRP3 inflammasome in macrophages
Article Snippet: .. After deparaffinization of tissue, rehydration, and antigen retrieval, sections were treated with anti-NLRP3 (Abcam, ab214185) and anti-Mac2 (Cedarlane, CL8942LE), anti-MPO (R&D Systems, AF3667), anti-CD79b (Abcam, ab134147), anti-BTK (Sigma-Aldrich, SAB4502936), anti-hResistin (R&D Systems, AF1359), or anti-RELMα (R&D Systems, MAB1523) antibodies overnight at 4°C and then with Alexa Fluor 488-donkey anti-mouse IgG (Jackson ImmunoResearch, 715-545-150) and Cy3-donkey anti-rabbit IgG (Jackson ImmunoResearch, 711-166-152) for double fluorescence staining. .. Sections were then incubated with the appropriate fluorochrome-coupled secondary antibody (Jackson ImmunoResearch).

Staining:

Article Title: Sex-specific angiogenic responses in endothelial cells—role of the pluripotency factor OCT4
Article Snippet: .. To assess macrophage infiltration within injured skin, immunofluorescence staining was performed using an anti-MAC2 [Cedarlane; CL8942AP; 1:500] antibody with 4,6-diamidino-2-phenylindole (DAPI). ..

Article Title: Lipid lowering alone fails to limit atherosclerosis progression and neutrophilic inflammation in middle-aged mice
Article Snippet: In addition, for Mac2 and αSMA stains, sections were permeabilized in a solution containing 0.01%-0.05% Triton X-100 (cat# 9036-19-5, Sigma Aldrich Inc, St. Louis, MO, USA) prior to blocking. .. After brief washes, samples were stained with either anti-Mac2 (cat# CL8942AP, Cedarlane Labs, Burlington, ON, USA) at 1:10000, anti-Histone H3 (citrulline R2 + R8 + R17) (cat#AB281584, clone RM1001, Abcam, Waltham, MA, USA) at 1:500, or anti-smooth muscle actin (cat#. 23081-1-AP, Proteintech, Rosemont, IL, USA) at 1:1000 in 1%BSA. .. Secondary antibodies used were Alexa Fluor 594 anti-rat (cat# A-11007, Thermo Fisher Scientific, Carlsbad, CA, USA) (Mac2) and Alexa Fluor 594 anti-rabbit (cat# A-11037, Thermo Fisher Scientific, Carlsbad, CA, USA) (H3Cit and αSMA).

Article Title: Chronic Glaucoma Induced in Rats by a Single Injection of Fibronectin-Loaded PLGA Microspheres: IOP-Dependent and IOP-Independent Neurodegeneration.
Article Snippet: .. Sections were stained with haematoxylin/eosin and mounted with DPX mounting medium or incubated overnight at 4 ◦C with the following primary antibodies: anti-fibronectin (AB2033, Chemicon), 1:100; anti-Brn3a (14A6, Santa Cruz Biotechnology, Dallas, TX, USA), 1:50; anti-GFAP (Z0334, Agilent, Dako, Santa Clara, CA, USA), 1:500; anti-Mac2 (CL8942LE, Cedarlane, Burlington, Canada) 1:50. ..

Incubation:

Article Title: Loss of TIM4-Dependent Efferocytosis in Kupffer Cells Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Article Snippet: For immunofluorescence experiments, human liver sections were incubated at 4 °C overnight with anti-human TIM4 (Cell signaling technology, #75484T, RRID:AB_2799871, 1:200 dilution), anti-CD68 (Agilent, #GA60961-2, RRID:AB_2661840, 1:500 dilution), and anti-cleaved caspase3 (Cell signaling technology, # 9661, RRID:AB_2341188, 1:100 dilution) in PBS containing 1% donkey serum. .. Mouse liver sections were incubated at 4 °C overnight with anti-mouse TIM4 (RD, #AF2826, RRID:AB_2201844, 1:200 dilution), anti-Clec4f (RD, #MAB2784, RRID:AB_2081338, 1:250 dilution), anti-Mac2 (Cedarlane, #CL8942AP, RRID:AB_10060357, 1:500 dilution), anti-F4/80 (Cell signaling technology, #70076s, RRID:AB_2799771, 1:200), anti-osteopontin (Opn, RD, #AF808, RRID:AB_2194992, 1:100 dilution), anti-α-smooth muscle actin (Sigma, #C6198, RRID:AB_476856, 1:100 dilution) and anti-cleaved caspase3 (Cell signaling technology, # 9661, RRID:AB_2341188, 1:100 dilution) in PBS containing 1% donkey serum. ..

Article Title: Nucleoporin93 limits Yap activity to prevent endothelial cell senescence
Article Snippet: .. Adjacent tissue sections were incubated with the following primary antibodies (4°C, overnight): anti‐Nup93 (1:500, Lusk Lab, Yale University); anti‐γH2AX (1:200, Sigma‐Aldrich, 05‐636); anti‐Mac2 (1:100, Cedarlane, CL8942AP); anti‐Yap (1:200, Santa Cruz, sc101199); anti‐VWF (1:200, Abcam, ab11713). ..

Immunofluorescence:

Immunohistochemistry:

Article Title: The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
Article Snippet: Antibody , Anti-ACTIN (Mouse, monoclonal) , Sigma , Cat# A1978, RRID: AB_4766 , WB (1:5000). .. Antibody , Anti-MAC2 (Rat, monoclonal) , Accurate/CEDARLANE , Cat# CL-8942AP, RRID: AB_10060357 , IHC (1:1000). .. Recombinant DNA reagent , LeveV2-vector , Addgene , 52961 , .

Image Search Results

Atherosclerosis regression is incomplete in Jak2 VF MPN mice with moderate cholesterol lowering. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 34, 55, 55, 54, 16, 16 for Ctrl mice, n = 31, 55, 49, 39, 17, 16 for Jak2 VF mice, for weeks 0, 5, 11, 15, 17.5, 21 respectively). P = 0.028, <0.0001, <0.0001, <0.0001, 0.0005, <0.0001 (Ctrl vs. Jak2 VF at weeks 0, 5, 11, 15, 17.5, and 21, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 15–23. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.052 ( Jak2 VF Baseline vs. LDL Lowering). E: Necrotic core area, n = 15–23. P = 0.0079 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0002 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.0003 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 15–24. P = 0.02 (Ctrl Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 15–24. P = 0.006 (Ctrl Baseline vs. LDL Lowering), P = 0.16 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Two-way ANOVA with Tukey’s multiple comparisons test (D, E, G, and I). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Atherosclerosis regression is incomplete in Jak2 VF MPN mice with moderate cholesterol lowering. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 34, 55, 55, 54, 16, 16 for Ctrl mice, n = 31, 55, 49, 39, 17, 16 for Jak2 VF mice, for weeks 0, 5, 11, 15, 17.5, 21 respectively). P = 0.028, <0.0001, <0.0001, <0.0001, 0.0005, <0.0001 (Ctrl vs. Jak2 VF at weeks 0, 5, 11, 15, 17.5, and 21, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 15–23. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.052 ( Jak2 VF Baseline vs. LDL Lowering). E: Necrotic core area, n = 15–23. P = 0.0079 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0002 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.0003 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 15–24. P = 0.02 (Ctrl Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 15–24. P = 0.006 (Ctrl Baseline vs. LDL Lowering), P = 0.16 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Two-way ANOVA with Tukey’s multiple comparisons test (D, E, G, and I). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Article Snippet: Following blocking, sections were incubated with the following primary antibodies at the indicated concentrations overnight at 4 °C in a humidified chamber: Absent in melanoma 2 (AIM2) (Abcam, ab119791, 1:250), Cleaved GasD (Cell Signaling, 10137, 10 μg/ml), c-Myc (Cell Signaling, 5605, 5.76 μg/ml), Ki67 (Abcam, ab15580, 9 μg/ml), MAC2 (Cedarlane, CL8942AP 1 μg/ml), MAC2 conjugated to Alexa Fluor 488 (Cedarlane, CL8942AF4, 1 μg/ml), mer proto-oncogene tyrosine kinase (MerTK) (R&D, BAF591, 2 μg/ml), pγH2AX (Cell Signaling, 9718, 0.74 μg/ml), ZsGreen (Thermo Fisher Scientific, TA180002, 10 μg/ml), triggering receptor expressed on myeloid cells 2 (TREM2) (Denali, 4D9 DC1847, 1:100).

Techniques: Clinical Proteomics, Staining

Aggressive cholesterol lowering normalizes regression in Jak2 VF MPN lesions. A: Study design, created with BioRender.com. B: Plasma cholesterol (n = 5, 38, 19, 18, and 18 for Ctrl mice, n = 5, 37, 15, 16, and 15 for Jak2 VF mice, for weeks 0, 4, 13, 15, and 18, respectively). P = 0.0041 for genotype effect by two-way ANOVA with Geisser-Greenhouse correction, P = 0.011, 0.048, 0.056, and 0.0008 (Ctrl vs. Jak2 VF at weeks 0, 4, 13, and 15, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). Figures 1 and 4 represent independent regression cohorts performed separately; therefore, absolute lesion area should be compared within each cohort rather than between figures. E: Necrotic core area, n = 13–20. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0006 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.90 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. LDL Lowering), P = 0.0002 ( Jak2 VF Baseline vs. LDL Lowering), P = 0.02 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 13–20. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D, G, and I). Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Kruskal-Wallis test with Dunn’s multiple comparisons test (E). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Aggressive cholesterol lowering normalizes regression in Jak2 VF MPN lesions. A: Study design, created with BioRender.com. B: Plasma cholesterol (n = 5, 38, 19, 18, and 18 for Ctrl mice, n = 5, 37, 15, 16, and 15 for Jak2 VF mice, for weeks 0, 4, 13, 15, and 18, respectively). P = 0.0041 for genotype effect by two-way ANOVA with Geisser-Greenhouse correction, P = 0.011, 0.048, 0.056, and 0.0008 (Ctrl vs. Jak2 VF at weeks 0, 4, 13, and 15, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). Figures 1 and 4 represent independent regression cohorts performed separately; therefore, absolute lesion area should be compared within each cohort rather than between figures. E: Necrotic core area, n = 13–20. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0006 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.90 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. LDL Lowering), P = 0.0002 ( Jak2 VF Baseline vs. LDL Lowering), P = 0.02 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 13–20. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D, G, and I). Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Kruskal-Wallis test with Dunn’s multiple comparisons test (E). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Techniques: Clinical Proteomics, Staining

Cholesterol lowering suppresses Jak2 VF macrophage proliferation and DNA damage. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 79, 78, and 78 for Baseline mice for weeks 3, 11, and 15, respectively; n = 13, 14 for Ctrl Progression mice, n = 16, 16 for Ctrl LDL Lowering mice, n = 15, 15 for Jak2 VF Progression mice, n = 16, 16 for Jak2 VF LDL Lowering mice, for weeks 18 and 23, respectively). C: Images of aortic root lesions for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 14–16. P = 0.01 (Baseline vs. Jak2 VF Progression), P = 0.051 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). E: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–16. P = 0.04 (Baseline vs. Jak2 VF Progression), P = 0.013 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. G: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 14–16. H: Images of aortic root lesions for MAC2 ( Red ), Ki67 ( White ), and ZsGreen ( Green ). Scale bar, 60 μm. White arrows , macrophages double positive for Ki67 and ZsGreen. I: Macrophages positive for both Ki67 and ZsGreen per section, n = 13–15. P = 0.0019 (Baseline vs. Jak2 VF Progression), P = 0.0006 (Ctrl Progression vs. Jak2 VF Progression), P = 0.0003 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). J: Macrophages positive for Ki67 but negative for ZsGreen per section, n = 13–16. K: Images of aortic root lesions stained for pγH2AX ( Red ), ZsGreen ( Green ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows, pγH2AX positive cells. L: Log 10 transformed cells double positive for pγH2AX and ZsGreen in lesions with the addition of constant 1, n = 13–16. P = 0.0024 (Baseline vs. Jak2 VF Progression), P = 0.0019 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). M: Log 10 transformed cells positive for pγH2AX but negative for ZsGreen in lesions with the addition of constant 1, n = 13–16. All quantifications shown as mean ± s.e.m. One-way ANOVA with Holm–Sidak’s multiple comparisons test (D and E). Kruskal–Wallis test with Dunn’s multiple comparison’s test (G, I, J, L, and M). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; pγH2AX, phosphorylated histone H2A.X.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Cholesterol lowering suppresses Jak2 VF macrophage proliferation and DNA damage. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 79, 78, and 78 for Baseline mice for weeks 3, 11, and 15, respectively; n = 13, 14 for Ctrl Progression mice, n = 16, 16 for Ctrl LDL Lowering mice, n = 15, 15 for Jak2 VF Progression mice, n = 16, 16 for Jak2 VF LDL Lowering mice, for weeks 18 and 23, respectively). C: Images of aortic root lesions for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 14–16. P = 0.01 (Baseline vs. Jak2 VF Progression), P = 0.051 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). E: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–16. P = 0.04 (Baseline vs. Jak2 VF Progression), P = 0.013 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. G: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 14–16. H: Images of aortic root lesions for MAC2 ( Red ), Ki67 ( White ), and ZsGreen ( Green ). Scale bar, 60 μm. White arrows , macrophages double positive for Ki67 and ZsGreen. I: Macrophages positive for both Ki67 and ZsGreen per section, n = 13–15. P = 0.0019 (Baseline vs. Jak2 VF Progression), P = 0.0006 (Ctrl Progression vs. Jak2 VF Progression), P = 0.0003 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). J: Macrophages positive for Ki67 but negative for ZsGreen per section, n = 13–16. K: Images of aortic root lesions stained for pγH2AX ( Red ), ZsGreen ( Green ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows, pγH2AX positive cells. L: Log 10 transformed cells double positive for pγH2AX and ZsGreen in lesions with the addition of constant 1, n = 13–16. P = 0.0024 (Baseline vs. Jak2 VF Progression), P = 0.0019 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). M: Log 10 transformed cells positive for pγH2AX but negative for ZsGreen in lesions with the addition of constant 1, n = 13–16. All quantifications shown as mean ± s.e.m. One-way ANOVA with Holm–Sidak’s multiple comparisons test (D and E). Kruskal–Wallis test with Dunn’s multiple comparison’s test (G, I, J, L, and M). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; pγH2AX, phosphorylated histone H2A.X.

Techniques: Clinical Proteomics, Transformation Assay, Fluorescence, Staining

Moderate cholesterol lowering reverses macrophage AIM2 inflammasome activation, DNA damage, and proliferation in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 15–24. P = 0.021 (Ctrl Baseline vs. Jak2 VF Baseline). C: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in necrotic cores with the addition of constant 1, n = 15–24. P = 0.0008 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.032 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). D: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. E: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 15–24. P = 0.024 ( Jak2 VF Baseline vs. LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), AIM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , AIM2 positive macrophages. G: Log 10 transformed AIM2 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.03 ( Jak2 VF Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. I: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 15–23. P = 0.0019 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.045 ( Jak2 VF Baseline vs. LDL Lowering). J: Images of aortic root lesions stained for MAC2 ( Green ), Ki67 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , Ki67 positive macrophages. K: Log 10 transformed Ki67 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0019 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B and C). Kruskal–Wallis test with Dunn’s multiple comparisons test (E, G, I, and K). AIM2, absent in melanoma 2; DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Moderate cholesterol lowering reverses macrophage AIM2 inflammasome activation, DNA damage, and proliferation in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 15–24. P = 0.021 (Ctrl Baseline vs. Jak2 VF Baseline). C: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in necrotic cores with the addition of constant 1, n = 15–24. P = 0.0008 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.032 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). D: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. E: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 15–24. P = 0.024 ( Jak2 VF Baseline vs. LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), AIM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , AIM2 positive macrophages. G: Log 10 transformed AIM2 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.03 ( Jak2 VF Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. I: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 15–23. P = 0.0019 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.045 ( Jak2 VF Baseline vs. LDL Lowering). J: Images of aortic root lesions stained for MAC2 ( Green ), Ki67 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , Ki67 positive macrophages. K: Log 10 transformed Ki67 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0019 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B and C). Kruskal–Wallis test with Dunn’s multiple comparisons test (E, G, I, and K). AIM2, absent in melanoma 2; DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Techniques: Activation Assay, Staining, Transformation Assay, Fluorescence, Imaging

Moderate cholesterol lowering reverses impaired efferocytosis in Jak2 VF MPN lesions while increasing TREM2 Hi macrophages in control and Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), MerTK ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Percentage of MAC2 positive area double positive for MerTK and MAC2, n = 15–23. P = 0.02 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). C: Images of aortic root lesions stained for MAC2 ( Green ), TREM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Percentage of MAC2 positive area double positive for TREM2 and MAC2, n = 15–24. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). E: Images of in situ efferocytosis in aortic root lesions: MAC2 ( Green ), TUNEL ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , nuclei double positive for TUNEL and MAC2. White wedges , nuclei positive for TUNEL but negative for MAC2. F: Percentage of TUNEL positive nuclei also positive for MAC2. P = 0.011 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.021 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels, n = 13–24. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D). Kruskal-Wallis test with Dunn’s multiple comparisons test (B and F). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MerTK, mer proto-oncogene tyrosine kinase; MPN, myeloproliferative neoplasm; TREM2, triggering receptor expressed on myeloid cells 2.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Moderate cholesterol lowering reverses impaired efferocytosis in Jak2 VF MPN lesions while increasing TREM2 Hi macrophages in control and Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), MerTK ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Percentage of MAC2 positive area double positive for MerTK and MAC2, n = 15–23. P = 0.02 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). C: Images of aortic root lesions stained for MAC2 ( Green ), TREM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Percentage of MAC2 positive area double positive for TREM2 and MAC2, n = 15–24. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). E: Images of in situ efferocytosis in aortic root lesions: MAC2 ( Green ), TUNEL ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , nuclei double positive for TUNEL and MAC2. White wedges , nuclei positive for TUNEL but negative for MAC2. F: Percentage of TUNEL positive nuclei also positive for MAC2. P = 0.011 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.021 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels, n = 13–24. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D). Kruskal-Wallis test with Dunn’s multiple comparisons test (B and F). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MerTK, mer proto-oncogene tyrosine kinase; MPN, myeloproliferative neoplasm; TREM2, triggering receptor expressed on myeloid cells 2.

Techniques: Control, Staining, In Situ, TUNEL Assay, Imaging

Aggressive cholesterol lowering more strongly decreases macrophage pyroptosis and DNA damage in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–20. P = 0.0064 for genotype effect and P = 0.021 for treatment effect by two-way ANOVA. C: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. D: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 13–20. P = 0.023 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.005 ( Jak2 VF Baseline vs. LDL Lowering). E: Representative immunoblot analysis of full-length and cleaved GasD in CD11b + splenocytes. F: Log 10 transformed densitometric quantification of the ratio of cleaved GasD to full-length GasD from E with the addition of constant 1. n = 7–8 biological replicates. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0046 ( Jak2 VF Baseline vs. LDL Lowering). G: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. H: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 14–20. P = 0.016 (Ctrl Baseline vs. LDL Lowering), P = 0.0016 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B, D, F, and H). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MFI, mean fluorescence intensity; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Aggressive cholesterol lowering more strongly decreases macrophage pyroptosis and DNA damage in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–20. P = 0.0064 for genotype effect and P = 0.021 for treatment effect by two-way ANOVA. C: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. D: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 13–20. P = 0.023 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.005 ( Jak2 VF Baseline vs. LDL Lowering). E: Representative immunoblot analysis of full-length and cleaved GasD in CD11b + splenocytes. F: Log 10 transformed densitometric quantification of the ratio of cleaved GasD to full-length GasD from E with the addition of constant 1. n = 7–8 biological replicates. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0046 ( Jak2 VF Baseline vs. LDL Lowering). G: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. H: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 14–20. P = 0.016 (Ctrl Baseline vs. LDL Lowering), P = 0.0016 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B, D, F, and H). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MFI, mean fluorescence intensity; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Techniques: Staining, Transformation Assay, Western Blot, Fluorescence

Podocyte damage and inflammatory changes are worsened by HPD in systemic GC-A knockout mice. ( a ) Immunohistochemical (IHC) staining for WT-1 in glomerulus. The graph shows the number of WT-1-positive cells per glomerulus as quantitative analysis. ( b ) IF staining for nephrin in each group. Scale Bar represents 50 μm. ( c ) Representative images of electron microscopic analysis in each group. The graphs indicate quantitative analysis of foot process width and GBM thickness. Scale Bar represents 1 μm. ( d ) IHC staining of MAC2 in glomerulus (▶). The graph shows the number of MAC2-positive macrophages per glomerulus. Scale Bar represents 50 μm. ( e , f ) Glomerular mRNA expression levels of Tgfb1 , Ctgf , Serpine1 , Ccl2 , Emr1 , Icam1 , and Vcam1 in each group. ( g ) Renal mRNA expression levels of Agt , Ren1 , and Sgk1 in each group. β-Actin ( Actb ) was used as internal control. Values are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, NS; not significant.

Journal: Scientific Reports

Article Title: Finerenone ameliorates diabetic kidney disease exacerbated by deletion of natriuretic peptide/guanylyl cyclase-A signaling and dietary high-protein load

doi: 10.1038/s41598-025-25362-0

Figure Lengend Snippet: Podocyte damage and inflammatory changes are worsened by HPD in systemic GC-A knockout mice. ( a ) Immunohistochemical (IHC) staining for WT-1 in glomerulus. The graph shows the number of WT-1-positive cells per glomerulus as quantitative analysis. ( b ) IF staining for nephrin in each group. Scale Bar represents 50 μm. ( c ) Representative images of electron microscopic analysis in each group. The graphs indicate quantitative analysis of foot process width and GBM thickness. Scale Bar represents 1 μm. ( d ) IHC staining of MAC2 in glomerulus (▶). The graph shows the number of MAC2-positive macrophages per glomerulus. Scale Bar represents 50 μm. ( e , f ) Glomerular mRNA expression levels of Tgfb1 , Ctgf , Serpine1 , Ccl2 , Emr1 , Icam1 , and Vcam1 in each group. ( g ) Renal mRNA expression levels of Agt , Ren1 , and Sgk1 in each group. β-Actin ( Actb ) was used as internal control. Values are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, NS; not significant.

Article Snippet: Primary antibodies used for immunohistochemical and immunofluorescence studies were anti-GC-A antibody (GTX109810, GeneTex, Inc., Irvine, CA, USA), anti-MAC2 antibody (CL8942F, Cedarlane, Ontario, Canada), anti-Wilms tumor 1 (WT1) antibody (sc-15421, Santa Cruz Biotechnology, Dallas, TX), anti-nephrin antibody (AF3159, R&D Systems, Inc., Minneapolis, MN, USA), and anti-Tie2 antibody (AF762, R&D Systems, Inc.).

Techniques: Knock-Out, Immunohistochemical staining, Immunohistochemistry, Staining, Expressing, Control

Podocyte damage and profibrotic changes are worsened by HPD in endothelial cell-specific GC-A knockout mice. ( a ) IHC staining of WT-1 in glomerulus. The graph shows the number of WT-1-positive cells per glomerulus as quantitative analysis. Scale Bar represents 50 μm. ( b ) IF staining for nephrin. Scale Bar represents 50 μm. ( c ) Representative images of electron microscopic analysis in each group. The graphs indicate quantitative analysis of foot process width and GBM thickness. Scale Bar represents 1 μm. ( d ) IHC staining of MAC2 in glomerulus (▶). The graph shows the number of MAC2-positive macrophages per glomerulus. Scale Bar represents 100 μm. ( e ) Glomerular mRNA expression levels of Tgfb1 , Ctgf , Fn1 , Serpine1 , Ccl2 , and Emr1 in each group. ( f ) Renal mRNA levels of Fn1 , Serpine1 , Lcn2 , Agt, and Sgk1 in each group. β-Actin ( Actb ) was used as internal control. Values are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, NS; not significant.

Journal: Scientific Reports

Article Title: Finerenone ameliorates diabetic kidney disease exacerbated by deletion of natriuretic peptide/guanylyl cyclase-A signaling and dietary high-protein load

doi: 10.1038/s41598-025-25362-0

Figure Lengend Snippet: Podocyte damage and profibrotic changes are worsened by HPD in endothelial cell-specific GC-A knockout mice. ( a ) IHC staining of WT-1 in glomerulus. The graph shows the number of WT-1-positive cells per glomerulus as quantitative analysis. Scale Bar represents 50 μm. ( b ) IF staining for nephrin. Scale Bar represents 50 μm. ( c ) Representative images of electron microscopic analysis in each group. The graphs indicate quantitative analysis of foot process width and GBM thickness. Scale Bar represents 1 μm. ( d ) IHC staining of MAC2 in glomerulus (▶). The graph shows the number of MAC2-positive macrophages per glomerulus. Scale Bar represents 100 μm. ( e ) Glomerular mRNA expression levels of Tgfb1 , Ctgf , Fn1 , Serpine1 , Ccl2 , and Emr1 in each group. ( f ) Renal mRNA levels of Fn1 , Serpine1 , Lcn2 , Agt, and Sgk1 in each group. β-Actin ( Actb ) was used as internal control. Values are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, NS; not significant.

Techniques: Knock-Out, Immunohistochemistry, Staining, Expressing, Control

Review

mac2 (Cedarlane)

Structured Review

Images

Related Articles

Fluorescence:

Staining:

Incubation:

Immunofluorescence:

Immunohistochemistry:

Similar Products

Image Search Results